Novo Nordisk contests Danish lawsuit claiming $1.75 billion

COPENHAGEN (Reuters) - Danish insulin-maker Novo Nordisk said it would fight a lawsuit filed in a Danish court on Friday which alleges the company made misleading statements about its insulin business in the United States, the company said in a statement."Novo Nordisk disagrees with the allegations and is prepared to defend the company in this matter," the company said. The securities lawsuit was filed by a number of shareholders who claims compensation worth a total of 11.785 billion Danish..